Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses: 2010-2024

Historic Other Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Dec 2024 value amounting to $4.4 million.

  • Ironwood Pharmaceuticals' Other Accumulated Expenses fell 4.09% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 4.09%. This contributed to the annual value of $4.4 million for FY2024, which is 28.71% down from last year.
  • Ironwood Pharmaceuticals' Other Accumulated Expenses amounted to $4.4 million in FY2024, which was down 28.71% from $6.2 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Other Accumulated Expenses ranged from a high of $6.2 million in FY2023 and a low of $2.6 million during FY2020.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $4.4 million (2024), whereas its average is $4.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 74.84% in 2020, then surged by 72.14% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $2.6 million in 2020, then surged by 32.38% to $3.4 million in 2021, then climbed by 4.59% to $3.6 million in 2022, then soared by 72.14% to $6.2 million in 2023, then decreased by 28.71% to $4.4 million in 2024.